Rocket Pharmaceuticals (9IP1) Ownership - Who Owns Rocket Pharmaceuticals?
Rocket Pharmaceuticals (9IP1) Ownership Overview
- 20.46% Insiders
- 15.84% Mutual Funds
- 0.43% Other Institutional Investors
- 12.27% ETFs
- 51.00% Public Companies and Individual Investors
The ownership structure of Rocket Pharmaceuticals (DE:9IP1) stock is a mix of institutional, retail, and individual investors. Approximately 28.54% of the company’s stock is owned by Institutional Investors, 20.46% is owned by Insiders, and 51.00% is owned by Public Companies and Individual Investors.
The ownership structure of Rocket Pharmaceuticals (DE:9IP1) stock is a mix of institutional, retail, and individual investors. Approximately 28.54% of the company’s stock is owned by Institutional Investors, 20.46% is owned by Insiders, and 51.00% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 14, 2026 | Martin Wilson | $256,238 | |
| Aug 19, 2026 | Gaurav Shah | $7,750 | |
| Aug 19, 2026 | Martin Wilson | $2,133 | |
| Aug 16, 2026 | Martin Wilson | $11,806 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | €258,837 | |
| Dec 31, 2025 | Entrypoint Capital, Llc | €338,202 | |
| Dec 31, 2025 | Maverick Capital Ltd | €8,821,016 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Roderick Wong | 18,263,956 | Insider | 16.64% | 42,208,002 |
| BlackRock, Inc. | 9,923,962 | Institution | 9.04% | 22,934,276 |
| Vanguard | 4,628,957 | Institution | 4.22% | 10,697,520 |
| Ishares | 4,594,404 | Institution | 4.19% | 10,617,668 |
| Lee Ainslie | 3,923,963 | Institution | 3.57% | 9,068,278 |
| Vanguard Index Funds | 3,701,156 | Institution | 3.37% | 8,553,372 |
| Vanguard Horizon Funds | 2,702,086 | Institution | 2.46% | 6,244,521 |
| Federated Hermes Mdt Series | 1,470,538 | Institution | 1.34% | 3,398,413 |
| Gaurav Shah | 1,462,832 | Insider | 1.33% | 3,380,605 |
| Fidelity Salem Street Trust | 1,115,893 | Institution | 1.02% | 2,578,829 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 3,701,156 | Institution | 3.37% | 8,553,372 |
| Vanguard Horizon Funds | 2,702,086 | Institution | 2.46% | 6,244,521 |
| Federated Hermes Mdt Series | 1,470,538 | Institution | 1.34% | 3,398,413 |
| Fidelity Salem Street Trust | 1,115,893 | Institution | 1.02% | 2,578,829 |
| Blackrock Funds | 968,263 | Institution | 0.88% | 2,237,656 |
| Fidelity Concord Street Trust | 936,674 | Institution | 0.85% | 2,164,654 |
| Bridge Builder Trust | 762,654 | Institution | 0.69% | 1,762,493 |
| Vanguard Explorer Fund | 618,517 | Institution | 0.56% | 1,429,393 |
| Vanguard Scottsdale Funds | 609,510 | Institution | 0.56% | 1,408,578 |
| Dfa Investment Dimensions Group Inc | 524,181 | Institution | 0.48% | 1,211,382 |
FAQ
Who Owns Rocket Pharmaceuticals (DE:9IP1)?
According to the latest TipRanks data, approximately 28.54% of the company's stock is held by institutional investors, 20.46% is held by insiders, and 51.00% is held by public companies and individual investors.
What percentage of Rocket Pharmaceuticals (DE:9IP1) stock is held by institutional investors?
According to the latest TipRanks data, approximately 28.54% of Rocket Pharmaceuticals (DE:9IP1) stock is held by institutional investors: 15.84% by mutual funds, 12.27% by ETFs and 0.43% by other institutional investors.
What percentage of Rocket Pharmaceuticals (DE:9IP1) stock is held by retail investors?
According to the latest TipRanks data, approximately 51.00% of Rocket Pharmaceuticals (DE:9IP1) stock is held by public companies and individual investors.
Who owns the most shares of Rocket Pharmaceuticals (DE:9IP1)?
RODERICK WONG owns the most shares of Rocket Pharmaceuticals (DE:9IP1).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
